Article

Daily Medication Pearl: Hyqvia Immune Globulin Infusion 10%

Hyqvia is an immune globulin with a recombinant human hyaluronidase indicated for the treatment of primary immunodeficiency in adults.

Medication Pearl of the Day: Hyqvia Immune Globulin Infusion 10%

Indication: Hyqvia is an immune globulin with a recombinant human hyaluronidase indicated for the treatment of primary immunodeficiency (PI) in adults.

Insight:

  • Dosing: May start from 7.5 g up to 30 g infusions depending on the patient.
  • Dosage forms: Comes in 10%, 2.5, 5-, 10-, 20-, and 30-gram proteins.
  • Adverse events: The most common adverse reactions observed in clinical trials in >5% of subjects were local reactions, headache, antibody formation against recombinant human hyaluronidase (rHuPH20), fatigue, nausea, pyrexia, and vomiting.
  • Mechanism of action: The immune globulin infusion 10% (human) provides the therapeutic effect of Hyqvia. The recombinant human hyaluronidase of Hyqvia increases dispersion and absorption of the immune globulin infusion 10% (human). The immune globulin infusion 10% (human) of Hyqvia supplies a broad spectrum of opsonizing and neutralizing IgG antibodies against a wide variety of bacterial and viral agents.

Source: HYQVIA [Immune Globulin Infusion 10% (Human) with Recombinant (fda.gov)

Related Videos
pharmacogenetics testing, adverse drug events, personalized medicine, FDA collaboration, USP partnership, health equity, clinical decision support, laboratory challenges, study design, education, precision medicine, stakeholder perspectives, public comment, Texas Medical Center, DNA double helix
Pharmacy, Advocacy, Opioid Awareness Month | Image Credit: pikselstock - stock.adobe.com
pharmacogenetics challenges, inter-organizational collaboration, dpyd genotype, NCCN guidelines, meta census platform, evidence submission, consensus statements, clinical implementation, pharmacotherapy improvement, collaborative research, pharmacist role, pharmacokinetics focus, clinical topics, genotype-guided therapy, critical thought
Hurricane Helene, Baxter plant, IV fluids shortage, health systems impact, injectable medicines, compounding solutions, patient care errors, clinical resources, operational consideration, fluid conservation, sterile water, temperature excursions, training considerations, patient safety, feedback request
Image Credit: © peopleimages.com - stock.adobe.com
Pharmacists, Education, Advocacy, Opioid Awareness Month | Image Credit: Jacob Lund - stock.adobe.com
TRUST-I and TRUST-II Trials Show Promising Results for Taletrectinib in ROS1+ NSCLC
World Standards Week 2024: US Pharmacopeia’s Achievements and Future Focus in Pharmacy Standards